Mexico
Tuberculosis profile
Population  2012 121 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.2 (2.1–2.3) 1.8 (1.7–1.9)
Mortality (HIV+TB only) 0.31 (0.25–0.39) 0.26 (0.21–0.32)
Prevalence  (includes HIV+TB) 40 (19–69) 33 (16–57)
Incidence  (includes HIV+TB) 27 (23–32) 23 (19–26)
Incidence (HIV+TB only) 1.6 (1.4–1.8) 1.3 (1.1–1.5)
Case detection, all forms (%) 75 (64–87)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 13 038 (66) Relapse 773 (47)
Smear-negative 757 (4) Treatment after failure 116 (7)
Smear-unknown / not done 1 924 (10) Treatment after default 272 (16)
Extrapulmonary 3 839 (19) Other 490 (30)
Other 139 (<1)      
Total new 19 697   Total retreatment 1 651  
           
Other (history unknown) 0        
Total new and relapse 20 470   Total cases notified 21 348  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.7 1.7 1.1
Age < 15 267 264 420
Laboratories 2012
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 2.7
Drug susceptibility testing (per 5 million population) 0.6
Is second-line drug susceptibility testing available? Yes, in and outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 86   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 72  
Retreatment 61  
TB/HIV 2012 Number (%)
TB patients with known HIV status 15 005 (70)
HIV-positive TB patients 1 233 (8)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 863 (70)
HIV-positive TB patients on antiretroviral therapy (ART) 298 (24)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.4 (2.1–2.8) 6.3 (5.1–7.8)
MDR-TB cases among notified pulmonary
TB cases
380 (330–440) 100 (84–130)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 13 (<1%) 148 (9%) 161
Laboratory-confirmed MDR-TB cases 5 109 114
Patients started on MDR-TB treatment     115
Financing TB control 2013
National TB programme budget (US$ millions) 20
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data